Gadodiamide

Identification

Name

Gadodiamide

Accession Number

DB00225

Description

Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.

Type

Small Molecule

Groups

Approved, Investigational

Structure

Similar Structures

Weight: Average: 573.66
Monoisotopic: 574.10225
Chemical Formula: C₁₆H₂₆GdN₅O₈

Synonyms

Gadodiamida
Gadodiamide
Gadodiamide anhydrous

External IDs

S-041

Pharmacology

Indication

For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Not Available

Mechanism of action

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.

Absorption

Not Available

Volume of distribution

200 ± 61 mL/kg

Protein binding

Not Available

Metabolism

There is no detectable biotransformation or decomposition of gadodiamide.

Route of elimination

Gadodiamide is eliminated primarily in the urine.

Half-life

Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.

Clearance

Renal cl=1.7 mL/min/kg
Plasma cl=1.8 mL/min/kg

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Abacavir	Gadodiamide may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acarbose	Gadodiamide may decrease the excretion rate of Acarbose which could result in a higher serum level.
Aceclofenac	Aceclofenac may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Acetaminophen	Gadodiamide may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Aclidinium	Gadodiamide may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Gadodiamide may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Gadodiamide which could result in a higher serum level.

Additional Data Available

Extended Description

Available for Purchase

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

Available for Purchase

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

Available for Purchase

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

Available for Purchase

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?

Learn More

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Gadodiamide hydrate	0RPE15QPL0	122795-43-1	WYKPQCVMUQQKCL-UHFFFAOYSA-K

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Omniscan	Solution	287 mg	Intravenous	Ge Healthcare	1997-03-25	Not applicable
Omniscan	Injection	287 mg/1mL	Intravenous	GE Healthcare Inc.	2002-04-19	Not applicable
Omniscan	Injection	287 mg/1mL	Intravenous	GE Healthcare Inc.	2006-09-21	Not applicable
Omniscan Liq IV 287mg/ml	Liquid		Intravenous	Sanofi	1994-12-31	1997-07-30

Additional Data Available

Application Number

Available for Purchase

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

Available for Purchase

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

Chemical Identifiers

UNII: 84F6U3J2R6
CAS number: 131410-48-5
InChI Key: HZHFFEYYPYZMNU-UHFFFAOYSA-K
InChI: InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3
IUPAC Name: gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)[(methylcarbamoyl)methyl]amino]ethyl})amino]acetate
SMILES: [Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O

References

General References

Not Available

External Links

PubChem Compound: 24847884
PubChem Substance: 46504789
ChemSpider: 135661
RxNav: 41144
ChEBI: 37333
PharmGKB: PA164784027
RxList: RxList Drug Page
Wikipedia: Gadodiamide

AHFS Codes

92:00.00 — Miscellaneous Therapeutic Agents

MSDS

Download (56.3 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Not Available	Chronic Kidney Disease (CKD) / Impaired kidney function	1
4	Not Yet Recruiting	Other	Cognitive Function / Contrast Media / Motor Function	1
3	Completed	Diagnostic	Anatomic renal artery stenosis	1
3	Completed	Diagnostic	Aorto-Iliac Stenosis / Arterial Occlusive Diseases	1

Pharmacoeconomics

Manufacturers

Ge healthcare

Packagers

Amersham Health Inc.
GE Healthcare Inc.

Dosage Forms

Form	Route	Strength
Injection, solution	Intravenous	287 mg/ml
Injection	Intravenous	287 mg/1mL
Injection, solution	Intravenous	287 mg/1mL
Injection, solution	Intravenous	0.5 mmol/ml
Liquid	Intravenous
Solution	Intravenous	287 mg
Solution	Intravenous	287 mg/ml

Prices

Unit description	Cost	Unit
Omniscan prefill plus syringe	7.02USD	ml
Omniscan 287 mg/ml vial	6.98USD	ml
Omniscan 287 mg/ml bottle	6.49USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
Unlock Additional Data
US5560903	No	1996-10-01	2013-10-01
US5362475	No	1994-11-08	2011-11-08
CA1335819	No	1995-06-06	2012-06-06

Additional Data Available

Filed On

Available for Purchase

The date on which a patent was filed with the relevant government.

Learn more

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	5.21 mg/mL	ALOGPS
logP	0.02	ALOGPS
logP	-8.7	ChemAxon
logS	-2.1	ALOGPS
pKa (Strongest Acidic)	1.02	ChemAxon
pKa (Strongest Basic)	8.34	ChemAxon
Physiological Charge	-2	ChemAxon
Hydrogen Acceptor Count	11	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	188.31 Å²	ChemAxon
Rotatable Bond Count	16	ChemAxon
Refractivity	132.4 m³·mol^-1	ChemAxon
Polarizability	40.47 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	-	0.9808
Blood Brain Barrier	+	0.62
Caco-2 permeable	-	0.5605
P-glycoprotein substrate	Substrate	0.7041
P-glycoprotein inhibitor I	Non-inhibitor	0.9016
P-glycoprotein inhibitor II	Non-inhibitor	0.9571
Renal organic cation transporter	Non-inhibitor	0.9031
CYP450 2C9 substrate	Non-substrate	0.8265
CYP450 2D6 substrate	Non-substrate	0.8189
CYP450 3A4 substrate	Non-substrate	0.5872
CYP450 1A2 substrate	Non-inhibitor	0.9416
CYP450 2C9 inhibitor	Non-inhibitor	0.9189
CYP450 2D6 inhibitor	Non-inhibitor	0.9566
CYP450 2C19 inhibitor	Non-inhibitor	0.8972
CYP450 3A4 inhibitor	Non-inhibitor	0.9864
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9927
Ames test	Non AMES toxic	0.8343
Carcinogenicity	Non-carcinogens	0.8563
Biodegradation	Not ready biodegradable	0.7604
Rat acute toxicity	1.9159 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9582
hERG inhibition (predictor II)	Non-inhibitor	0.9424

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available

Drug created on June 13, 2005 07:24 / Updated on November 30, 2020 13:38

Gadodiamide

Identification

Structure for Gadodiamide (DB00225)

Pharmacology

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn about our commercial Adverse Effects data.

Interactions

Products

Purchasing individual compounds or compound libraries for your research?

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra